This study aims to determine whether ketamine could improve the depressive symptom of perioperative patients. It will also examine the safety for administrating ketamine as an antidepressant intraoperatively and effects on anxiety, postoperative pain, and delirium (n=84).
Randomized, parallel-group Phase II/III trial evaluating intraoperative IV ketamine (0.5 mg/kg over 40 minutes at dural opening) versus volume-matched normal saline in patients with supratentorial brain tumour and moderate–severe perioperative depressive symptoms.
Primary outcomes include change in depressive symptoms and safety of intraoperative ketamine; secondary outcomes include anxiety, postoperative pain, and delirium. Eighty-four participants were enrolled.
IV ketamine 0.5 mg/kg at dural opening; 40-minute infusion.
Infused at dural opening over 40 minutes.
Volume-matched IV normal saline 0.5 ml/kg at dural opening; 40-minute infusion.
Volume- and duration-matched saline infusion.